KCP
ELDN icon

Kera Capital Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Kera Capital Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
40,208
+300
+0.8% +$1.09K 0.02% 618
2026
Q1 		$123K Buy
39,908
+138
+0.3% +$325 0.02% 558
2025
Q4 		$87.5K Buy
39,770
+14,000
+54% +$33.3K 0.01% 544
2025
Q3 		$66.7K Hold
25,770
– – 0.01% 414
2025
Q2 		$69.8K Hold
25,770
– – 0.01% 346
2025
Q1 		$87.4K Hold
25,770
– – 0.03% 183
2024
Q4 		$106K Buy
+25,770
New +$102K 0.03% 153

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Kera Capital Partners's ELDN Position: Q2 2026 in Review

Kera Capital Partners increased its Eledon Pharmaceuticals (ELDN) stake by 0.75% in Q2 2026, buying an estimated $1.09K and bringing the position to 40,208 shares worth $158K. The position accounts for 0.02% of the portfolio, ranked #618.

Kera Capital Partners first reported a position in ELDN in Q4 2024 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Kera Capital Partners held 40,208 shares of Eledon Pharmaceuticals worth $158K as of Q2 2026.
  • Kera Capital Partners bought 300 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.09K.
  • Eledon Pharmaceuticals made up 0.02% of Kera Capital Partners's portfolio in Q2 2026, its #618 holding.
  • Kera Capital Partners first reported a position in Eledon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.